Wealthedge Investment Advisors LLC Has $2.08 Million Holdings in Abbott Laboratories $ABT

Wealthedge Investment Advisors LLC boosted its stake in Abbott Laboratories (NYSE:ABT) by 31.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,909 shares of the healthcare product maker’s stock after purchasing an additional 5,529 shares during the quarter. Wealthedge Investment Advisors LLC’s holdings in Abbott Laboratories were worth $2,079,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories during the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of recent analyst reports. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. TD Cowen reiterated a “buy” rating and set a $115.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Piper Sandler reissued an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Thursday, August 13th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $118.67.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $114.50 on Thursday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock has a 50 day moving average price of $99.02 and a 200 day moving average price of $99.90. The stock has a market capitalization of $198.13 billion, a PE ratio of 37.06, a price-to-earnings-growth ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the previous year, the company earned $1.26 earnings per share. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.